Business Context and Reporting Period
Company: Tharimmune, Inc. (Note: Input metadata referenced "Canton Strategic Holdings, Inc.", but the filing text identifies the registrant as Tharimmune, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: June 13, 2025
Event: Entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $2.5 million (before fees and expenses).
- Securities Issued:
- 1,551,351 shares of Common Stock.
- Pre-Funded Warrants for 137,838 shares (Exercise Price: $0.001).
- Series A Warrants for 1,689,189 shares (Exercise Price: $1.29).
- Series B Warrants for 844,572 shares (Exercise Price: $3.00).
- Use of Proceeds: Clinical development and working capital.
- Placement Agent: President Street Global.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Transaction Terms
The primary material change is the execution of a Securities Purchase Agreement. Key terms include:
- Closing Date: Expected on June 20, 2025, subject to customary conditions.
- Warrant Terms:
- Series A and Series B Warrants are exercisable six months post-issuance with a 5.5-year term.
- Pre-Funded Warrants are immediately exercisable.
- Ownership Limitations: Holders (including affiliates) are restricted from exercising warrants if it results in ownership exceeding 4.99% of outstanding common stock (or 9.99% at the holder's election).
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to utilize net proceeds to advance clinical development efforts and support general working capital needs.
Risks and Contingencies: The transaction is contingent upon the satisfaction of customary closing conditions. The filing includes standard representations and warranties but does not detail specific new risks beyond the dilution inherent in the issuance of new shares and warrants.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $2.5 million gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.
- Assess the dilution impact of the 1,551,351 common shares and 2,671,599 total warrant shares on existing shareholders.
- Confirm the specific clinical development milestones the proceeds are intended to fund.
- Check for any subsequent filings regarding the actual net proceeds after deducting placement agent fees and offering expenses.